The global biopharmaceutical industry is about more than healthcare. It is a massive economic opportunity. Today, the sector is valued at over $1.77 trillion globally, with more than 5,500 active research companies driving growth. Dominant players like Johnson & Johnson, Roche, Merck, and Pfizer leverage their scale to bring new drugs to market. These companies coordinate billions of doses through supply chains that most people never think about.
But developing new drugs is expensive and risky. It takes an average of over a decade and $2.3 billion to bring a single drug to market. Ninety percent of drugs that reach clinical trials never get approved. This is why intellectual property protection matters so much. Without patents, companies would have no way to recover what they spend on failed experiments.
Biopharma is also no longer just about medicine. A strong biopharma sector creates high-paying jobs, drives technological progress, and helps countries respond to health crises. It has become a national security asset. Among the current global leaders, the United States and China stand out the most. The U.S. maintains its lead through innovation and IP protection, but its reliance on high prices creates a vulnerability. China is growing fast, and that gap is narrowing.
The U.S. Model
The United States has led global pharmaceutical production for decades. With over 1.2 million workers employed at wages well above the national average, the industry is built around high-value innovation. The U.S. currently accounts for 28.4 percent of global pharmaceutical production, making it first in the world.
Recent deal activity shows just how much money is moving through this sector. In 2025 alone, 129 mergers and acquisitions totaled about $138 billion. Much of this activity is driven by the upcoming loss of patent exclusivity for major drugs like Keytruda, which generated over $29 billion in sales in 2024. Rather than developing new drugs, many companies are simply buying existing ones.
The bigger issue is that the U.S. model is paying more for the same amount of care. According to IQVIA’s 2025 global medicines report, spending growth in the U.S. has been high while per-capita volume growth sits at just 0.4 percent. The U.S. increased its global market share by only 2.2 percentage points historically, a modest gain compared to what China has done.
Press enter or click to view image in full size
Figure 1: U.S. and China pharmaceutical market share trends (1995–2020)
China’s Rapid Ascent
China is a newer player in the global biopharma industry, but its growth has been remarkable. In 1995, China accounted for roughly 3 percent of global pharmaceutical production. By 2020, that number had climbed to 17.4 percent, a gain of 14.4 percentage points in just 25 years. For comparison, the U.S. grew by only 2.2 percentage points over the same period. China’s growth was 7 times faster than the United States, according to research from the Information Technology and Innovation Foundation.
This growth was not just about profit. China had a large population that needed access to medicine and lacked enough domestic supply to meet that demand. In the five years leading up to 2024, per-capita medicine use in China grew by about 4.4 percent annually, far outpacing competitors. Unlike the U.S., which grows revenue by raising prices, China focused on expanding access by keeping prices low and reaching more patients.
This difference shows up clearly in the data. North America shows high spending growth (around 45 percent) but almost no volume growth. China shows modest spending growth (around 15 percent) but significant volume growth (around 10 percent). These two countries are pursuing completely different strategies.
Press enter or click to view image in full size
Figure 2: Spending growth vs. volume growth comparison (2025–2029 projections)
Looking ahead, China is forecast to grow at 1.8 percent annually. That is more than four times the pace of the U.S. China is also no longer just manufacturing generic drugs. It now accounts for 29.5 percent of the global R&D pipeline. Chinese companies are responsible for 20 percent of drugs in development worldwide, and licensing deals between U.S. and Chinese biopharma companies hit record highs in 2024, a 280 percent increase from 2020.
Recent Policy, Investment, and Regulation
Both countries have made deliberate policy choices that reflect their different strategies. China’s “Made in China 2025” initiative and “Healthy China 2030” plan represent national efforts to transform the country from a generic drug manufacturer into an innovation hub. These policies included streamlined regulatory pathways, tax incentives for R&D, and special economic zones for pharmaceutical manufacturing. Between 2015 and 2024, China’s precision medicine market grew from almost nothing to over 286 billion RMB, and is projected to exceed 570 billion RMB by 2030.
The United States, meanwhile, has focused on protecting its innovation advantage through IP law and high drug prices. The Inflation Reduction Act of 2022 allowed Medicare to negotiate drug prices for the first time, but it only applies to a small number of drugs. American companies have responded to competitive pressure mostly through mergers and acquisitions, not by expanding access.
China’s regulatory reforms have also been significant. A 2017 overhaul of the drug registration system cut approval times dramatically. By 2024, China was approving innovative drugs at a pace comparable to the FDA. The government also created a national body to negotiate drug prices, forcing companies to accept lower margins in exchange for access to a massive patient base. This created the opposite dynamic from the U.S.: lower prices per dose, but far more patients served.
Divergent Strategies, Different Vulnerabilities
The contrast between these two approaches reveals fundamentally different priorities. The U.S. model bets on breakthrough innovation protected by strong IP rights, assuming that premium pricing will generate the returns needed to fund future research. China’s model bets on volume, tapping into a massive patient population that Western companies have largely ignored. China is now building real R&D capacity on top of that volume advantage. Its AI-powered pharmaceutical ecosystem expanded to 98 companies by 2024, with firms like Insilico Medicine advancing AI-discovered molecules into Phase II clinical trials.
The vulnerability of the American model becomes clear when you look at where growth is actually happening. The U.S. is spending more and reaching fewer people. China is spending less and reaching more. Over time, that is a difficult position to defend.
What This Means for the Future
The United States faces a structural problem. Its model is built around high prices and slow volume growth. That worked well when the U.S. had a near-monopoly on innovation. It works less well when a country with 1.4 billion people is catching up on both innovation and production at the same time.
The U.S. can learn from China’s strategy without copying it entirely. China has shown that expanding access does not have to come at the expense of innovation. The U.S. should look at ways to improve volume and global reach while keeping its lead in breakthrough research. Improving the pricing structure is no longer just a political debate; it is an economic necessity. Paying a premium for the same level of care is not sustainable.
A hybrid strategy is the most realistic path forward. That means continuing to invest heavily in novel drug development, where the U.S. still has a clear advantage, while also improving access at home and abroad. Strategic partnerships with other pharmaceutical leaders like Germany, the United Kingdom, and Switzerland could help the U.S. build the scale it currently lacks. Pharmaceutical leadership is not just an economic issue. It determines who has access to life-saving medicine on a global scale.
Conclusion
The competition for global pharmaceutical leadership is happening on two tracks. The U.S. leads in innovation, intellectual property, and premium pricing, which has produced some of the most important medicines in history. China is rising through volume production and expanded access, and is beginning to close the innovation gap as well.
The U.S. cannot afford to simply maintain the status quo. A hybrid approach, one that balances innovation with access, is the only viable long-term strategy. This is not a question of picking between innovation and volume. It is a question of whether the U.S. is willing to adapt before the gap gets smaller. The future of pharmaceutical leadership will belong to whoever can do both.